NeuroOne will announce Q4 and fiscal 2024 financial results on December 17, 2024, followed by a conference call.
Quiver AI Summary
NeuroOne Medical Technologies Corporation will announce its financial results for the fourth quarter and fiscal year ending September 30, 2024, on December 17, 2024, before the market opens. Following this, management will host a conference call and webcast at 9:00 a.m. Eastern time to discuss these results, provide a corporate update, and answer questions from participants. Interested parties can access the call via toll-free U.S. and international numbers, with a playback option available until December 31, 2024. NeuroOne focuses on developing minimally invasive solutions for neurological disorders, aiming to enhance surgical care and patient outcomes. Further information can be found on their website.
Potential Positives
- Announcement of upcoming financial results for Q4 and fiscal year 2024, indicating transparency and organizational accountability.
- Hosting an investor conference call suggests proactive engagement with stakeholders and potential for positive investor sentiment.
- Focus on improving surgical care options for neurological disorders highlights the company's commitment to innovation and patient care.
- Potential expansion into other medical applications showcases growth opportunities and diversification in the company's strategy.
Potential Negatives
- The release lacks specific financial results or projections, which may raise concerns among investors about the company's financial performance and transparency.
- The mention of being a "developmental stage company" could signal that the company is still in the early phases of its product pipeline, which might deter investors seeking more established companies.
- The focus on a wide range of potential applications suggests the company is still exploring avenues rather than having a clear, focused strategy, which may lead to investor uncertainty.
FAQ
What are the financial results release dates for NeuroOne?
NeuroOne will release its financial results for the fiscal fourth quarter and year on December 17, 2024.
When is the investor conference call scheduled?
The investor conference call is scheduled for December 17, 2024, at 9:00 a.m. Eastern time.
How can I participate in the NeuroOne conference call?
Participants can join via the U.S. toll-free number 888-506-0062 or the international dial-in 973-528-0011.
What topics will be discussed during the conference call?
The call will cover fourth quarter and fiscal year 2024 financial results and a corporate update, followed by a Q&A session.
Where can I access the call playback after it concludes?
The playback will be available until December 31, 2024, at 877-481-4010 in the U.S. and 919-882-2331 internationally.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$NMTC Insider Trading Activity
$NMTC insiders have traded $NMTC stock on the open market 2 times in the past 6 months. Of those trades, 0 have been purchases and 2 have been sales.
Here’s a breakdown of recent trading of $NMTC stock by insiders over the last 6 months:
- MARK CHRISTIANSON (Business Development Director) has traded it 2 times. They made 0 purchases and 2 sales, selling 27,989 shares.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$NMTC Hedge Fund Activity
We have seen 10 institutional investors add shares of $NMTC stock to their portfolio, and 9 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- AWM INVESTMENT COMPANY, INC. added 250,000 shares (+26.3%) to their portfolio in Q3 2024
- MAYO CLINIC removed 181,754 shares (-100.0%) from their portfolio in Q3 2024
- NANTAHALA CAPITAL MANAGEMENT, LLC removed 152,200 shares (-16.0%) from their portfolio in Q3 2024
- UBS GROUP AG removed 57,195 shares (-99.8%) from their portfolio in Q3 2024
- BLAIR WILLIAM & CO/IL added 55,556 shares (+inf%) to their portfolio in Q3 2024
- XTX TOPCO LTD added 26,408 shares (+inf%) to their portfolio in Q3 2024
- GEODE CAPITAL MANAGEMENT, LLC added 24,972 shares (+9.6%) to their portfolio in Q3 2024
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
EDEN PRAIRIE, Minn., Dec. 04, 2024 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, will release financial results for the fiscal fourth quarter and year ended September 30, 2024, before market open on December 17, 2024.
Management will host an investor conference call and webcast at 9:00 a.m. Eastern time on Tuesday, December 17, 2024 to discuss the Company’s fourth quarter and fiscal year 2024 financial results, provide a corporate update, and conclude with Q&A from telephone participants. To participate, please use the following infomaiton:
Fourth Quarter and Fiscal 2024 Earnings Conference Call
Date: Tuesday, December 17, 2024
Time: 9:00 a.m. Eastern time
U.S. Dial-In (Toll Free): 888-506-0062
International Dial-In: 973-528-0011
Participant Access Code: 603219
Webcast:
NMTC Fourth Quarter and Fiscal 2024 Earnings Conference Call
Please join at least five minutes before the start of the call to ensure timely participation.
A playback of the call will be available through December 31, 2024. To listen, please call 877-481-4010 within the United States or 919-882-2331 when calling internationally, using replay passcode 51728. A webcast replay will also be available using the webcast link above through December 17, 2025.
About NeuroOne
NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) is a developmental stage company committed to providing minimally invasive and hi-definition solutions for EEG recording, brain stimulation and ablation solutions for patients suffering from epilepsy, Parkinson's disease, dystonia, essential tremors, chronic pain due to failed back surgeries and other related neurological disorders that may improve patient outcomes and reduce procedural costs. The Company may also pursue applications for other areas such as depression, mood disorders, pain, incontinence, high blood pressure, and artificial intelligence. For more information, visit www.nmtc1.com .
IR Contact
MZ Group – MZ North America
[email protected]
